TY - JOUR
T1 - Alcohol-Related Liver Disease
T2 - Areas of Consensus, Unmet Needs and Opportunities for Further Study
AU - Szabo, Gyongyi
AU - Kamath, Patrick S.
AU - Shah, Vijay H.
AU - Thursz, Mark
AU - Mathurin, Philippe
N1 - Funding Information:
Potential conflict of interest: M.T. reports grants from Novartis, Gilead and Vital Therapeutics, and personal fees from Affimune outside the submitted work. P.M. reports personal fees from Verlyx and Gilead during the study, and personal fees from Gilead, Abbvie, MSD, Bayer Healthcare, Intercept, Sanofi and Verlyx outside the submitted work. G.S. consults for Terra Firma, Carlos Foundation, Glympse Bio, Quest Diagnostic, Arrow Diagnostic, GLG, Salix, Tobira and Allergan. G.S. has received funding from NIH-NIAAA, Gilead, Genfit, University of Florida, Intercept, Allergan, Novartis, SignaBlok and Shire. V.S. reports personal fees from Enterome, France; Vital Therapies, USA; Novartis Pharma, Switzerland; Durect Corporation, USA; Merck Research Laboratories, USA; Afimmune Ltd., Ireland outside the submitted work. P.K. has no conflicts of interest in relation to this manuscript.
Publisher Copyright:
© 2019 by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.
PY - 2019/5
Y1 - 2019/5
N2 - A joint meeting of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) was held in London on September 30 and October 1, 2017. The goals of the meeting were to identify areas of broad agreement and disagreement, develop consensus, and determine future directions to ultimately reduce the burden, morbidity, and mortality of alcohol-related liver disease (previously termed alcoholic liver disease). The specific aims of the meeting were to identify unmet needs and areas for future investigation, in order to reduce alcohol consumption, develop markers for diagnosis and prognosis of disease, and create a framework to test novel pharmacological agents with pre-specified treatment endpoints. A table summary of these goals and aims is provided in the context of epidemiology, current management strategies, next steps for future trials and translational science.
AB - A joint meeting of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) was held in London on September 30 and October 1, 2017. The goals of the meeting were to identify areas of broad agreement and disagreement, develop consensus, and determine future directions to ultimately reduce the burden, morbidity, and mortality of alcohol-related liver disease (previously termed alcoholic liver disease). The specific aims of the meeting were to identify unmet needs and areas for future investigation, in order to reduce alcohol consumption, develop markers for diagnosis and prognosis of disease, and create a framework to test novel pharmacological agents with pre-specified treatment endpoints. A table summary of these goals and aims is provided in the context of epidemiology, current management strategies, next steps for future trials and translational science.
UR - http://www.scopus.com/inward/record.url?scp=85060168295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060168295&partnerID=8YFLogxK
U2 - 10.1002/hep.30369
DO - 10.1002/hep.30369
M3 - Review article
C2 - 30645002
AN - SCOPUS:85060168295
SN - 0270-9139
VL - 69
SP - 2271
EP - 2283
JO - Hepatology
JF - Hepatology
IS - 5
ER -